Dimensional Fund Advisors LP Raises Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Dimensional Fund Advisors LP grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.4% during the 2nd quarter, Holdings Channel.com reports. The fund owned 1,197,084 shares of the medical research company’s stock after acquiring an additional 60,827 shares during the period. Dimensional Fund Advisors LP’s holdings in IQVIA were worth $253,125,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in IQV. Rise Advisors LLC purchased a new position in IQVIA in the 1st quarter worth approximately $31,000. Versant Capital Management Inc lifted its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Riverview Trust Co purchased a new stake in shares of IQVIA in the first quarter worth about $32,000. Opal Wealth Advisors LLC bought a new position in IQVIA during the second quarter valued at approximately $27,000. Finally, International Assets Investment Management LLC purchased a new position in IQVIA during the 2nd quarter valued at approximately $32,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 1.1 %

NYSE IQV opened at $242.67 on Thursday. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a market capitalization of $44.21 billion, a price-to-earnings ratio of 33.15, a price-to-earnings-growth ratio of 2.24 and a beta of 1.49. The company’s 50-day simple moving average is $239.74 and its two-hundred day simple moving average is $234.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.22 earnings per share. Equities analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. The Goldman Sachs Group began coverage on shares of IQVIA in a research report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price target on the stock. Evercore ISI boosted their target price on shares of IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Truist Financial boosted their price objective on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $266.67.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.